Welcome

By clicking "Continue to the HCP site," you are certifying that you are a licensed US healthcare professional (HCP) and a US resident.

If you are a patient who wants to learn more about VASCEPA, click vascepa.com

Dosing: Information about dosing, including direction for patients

Stethoscope icon

HCP resources

Downloadable resources
to support your practice

Get them now
Medical cross icon

Pharmacist resources

Downloadable resources for pharmacists dispensing VASCEPA

Get them now
Apple icon

Patient resources

Downloadable resources for your
patients

Get them now

This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policy page.

IMPORTANT SAFETY INFORMATION

• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter

• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur

INDICATIONS AND LIMITATIONS OF USE

• VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease

• VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin

• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)

• Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)

• Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing [email protected], or calling the FDA at 1-800-FDA-1088

• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see full Prescribing Information for more information on VASCEPA.

Visual representations are for illustrative purposes only. The capsule shown is not an identical representation of the product.

CO and VT prescribers only: Click here for statutory price disclosure information.

VASCEPA, Amarin, REDUCE-IT, and Vascepa/Amarin logos are registered trademarks of Amarin Pharmaceuticals Ireland Limited.

All other trademarks are the property of their respective companies.

© 2023 Amarin Pharmaceuticals Ireland Limited.  All rights reserved.  VAS-03038v14  02/23

This website, Vascepa.com, Vascepasavings.com, Truetoyourheart.com, and the corporation's website, amarincorp.com, are the only company-sanctioned websites pertaining to the Amarin group of companies or its product, Vascepa® (icosapent ethyl) capsules. The Amarin group of companies is not responsible for false or misleading materials contained on other non–Amarin-controlled websites or other social media sites.